A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1325 participants.

Also called NCT07361302

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,325 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07361302
  • EU CT 2025-522542-40-00
  • WHO UTN U1111-1323-6001
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Argentina, Australia, Bulgaria, China, Greece, Hungary, India, Indonesia, Kazakhstan, Malaysia, Norway, Romania, Spain, Taiwan, Thailand, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07361302. Randomized; no masking; primary purpose treatment. Start 2026-02-17 (actual); primary completion 2027-10-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
Acronym
TENACITY
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Standard of care treatment
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct07361302
Content hash
d2f8451ebf7bab1b89e002cc98ffd9c2febd591f97c78800e42a4873a6e9eb0b